{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:39:11Z","timestamp":1791859151837,"version":"4.3.4"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40262-019-00813-w","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T05:02:27Z","timestamp":1566277347000},"page":"173-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-3244","authenticated-orcid":false,"given":"Stan J. F.","family":"Hartman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Orri\u00ebns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Dia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel F.","family":"Schreuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,20]]},"reference":[{"issue":"2","key":"813_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0924-8579(98)00022-3","volume":"10","author":"MA van Houten","year":"1998","unstructured":"van Houten MA, Luinge K, Laseur M, Kimpen JL. Antibiotic utilisation for hospitalised paediatric patients. Int J Antimicrob Agents. 1998;10(2):161\u20134. \nhttps:\/\/doi.org\/10.1016\/S0924-8579(98)00022-3\n\n.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"813_CR2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s00134-014-3403-8","volume":"40","author":"JJ De Waele","year":"2014","unstructured":"De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, et al. Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med. 2014;40(9):1340\u201351. \nhttps:\/\/doi.org\/10.1007\/s00134-014-3403-8\n\n.","journal-title":"Intensive Care Med"},{"key":"813_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0000000000002817","author":"JJ Cies","year":"2017","unstructured":"Cies JJ, Moore WS 2nd, Enache A, Chopra A. Beta-lactam therapeutic drug management in the PICU. Crit Care Med. 2017. \nhttps:\/\/doi.org\/10.1097\/ccm.0000000000002817\n\n.","journal-title":"Crit Care Med."},{"issue":"5","key":"813_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/MCC.0000000000000229","volume":"21","author":"D Tsai","year":"2015","unstructured":"Tsai D, Lipman J, Roberts JA. Pharmacokinetic\/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. Curr Opin Crit Care. 2015;21(5):412\u201320. \nhttps:\/\/doi.org\/10.1097\/MCC.0000000000000229\n\n.","journal-title":"Curr Opin Crit Care."},{"issue":"6","key":"813_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498\u2013509. \nhttps:\/\/doi.org\/10.1016\/S1473-3099(14)70036-2\n\n.","journal-title":"Lancet Infect Dis."},{"key":"813_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","volume":"77","author":"SI Blot","year":"2014","unstructured":"Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2014concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3\u201311. \nhttps:\/\/doi.org\/10.1016\/j.addr.2014.07.006\n\n.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"813_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","volume":"49","author":"AA Udy","year":"2010","unstructured":"Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1\u201316. \nhttps:\/\/doi.org\/10.2165\/11318140-000000000-00000\n\n.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"813_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/CCM.0000000000000029","volume":"42","author":"AA Udy","year":"2014","unstructured":"Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*. Crit Care Med. 2014;42(3):520\u20137. \nhttps:\/\/doi.org\/10.1097\/CCM.0000000000000029\n\n.","journal-title":"Crit Care Med"},{"key":"813_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-4120-2","author":"E Dhont","year":"2018","unstructured":"Dhont E, Van Der Heggen T, De Jaeger A, Vande Walle J, De Paepe P, De Cock PA. Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients? Pediatr Nephrol. 2018. \nhttps:\/\/doi.org\/10.1007\/s00467-018-4120-2\n\n.","journal-title":"Pediatr Nephrol."},{"key":"813_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-019-04205-x","author":"T Van Der Heggen","year":"2019","unstructured":"Van Der Heggen T, Dhont E, Peperstraete H, Delanghe JR, Vande Walle J, De Paepe P, et al. Augmented renal clearance: a common condition in critically ill children. Pediatr Nephrol. 2019. \nhttps:\/\/doi.org\/10.1007\/s00467-019-04205-x\n\n.","journal-title":"Pediatr Nephrol."},{"issue":"12","key":"813_CR11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367. \nhttps:\/\/doi.org\/10.1056\/NEJMra035092\n\n.","journal-title":"N Engl J Med"},{"issue":"7","key":"813_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00134-017-4780-6","volume":"43","author":"T T\u00e4ngd\u00e9n","year":"2017","unstructured":"T\u00e4ngd\u00e9n T, Ramos Martin V, Felton TW, Nielsen EI, Marchand S, Bruggemann RJ, et al. The role of infection models and PK\/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017;43(7):1021\u201332. \nhttps:\/\/doi.org\/10.1007\/s00134-017-4780-6\n\n.","journal-title":"Intensive Care Med"},{"issue":"3","key":"813_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","volume":"40","author":"JJ De Waele","year":"2014","unstructured":"De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2014;40(3):380\u20137. \nhttps:\/\/doi.org\/10.1007\/s00134-013-3187-2\n\n.","journal-title":"Intensive Care Med"},{"issue":"5","key":"813_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ijantimicag.2017.01.009","volume":"49","author":"CJP Economou","year":"2017","unstructured":"Economou CJP, Wong G, McWhinney B, Ungerer JPJ, Lipman J, Roberts JA. Impact of beta-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents. 2017;49(5):589\u201394. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.009\n\n.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"813_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","volume":"9","author":"NG Jager","year":"2016","unstructured":"Jager NG, van Hest RM, Lipman J, Taccone FS, Roberts JA. Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Rev Clin Pharmacol. 2016;9(7):961\u201379. \nhttps:\/\/doi.org\/10.1586\/17512433.2016.1172209\n\n.","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"11","key":"813_CR16","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1093\/jac\/dky314","volume":"73","author":"G Wong","year":"2018","unstructured":"Wong G, Briscoe S, McWhinney B, Ally M, Ungerer J, Lipman J, et al. Therapeutic drug monitoring of beta-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother. 2018;73(11):3087\u201394. \nhttps:\/\/doi.org\/10.1093\/jac\/dky314\n\n.","journal-title":"J Antimicrob Chemother"},{"key":"813_CR17","unstructured":"MeSH Database. Anti-bacterial Agents [Pharmacological Action] \nhttps:\/\/www.ncbi.nlm.nih.gov\/mesh\/82000900\n\n. Accessed 01 Apr 2017."},{"issue":"6","key":"813_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/jac\/39.6.789","volume":"39","author":"MD Reed","year":"1997","unstructured":"Reed MD, Yamashita TS, Myers CM, Blumer JL. The pharmacokinetics of teicoplanin in infants and children. J Antimicrob Chemother. 1997;39(6):789\u201396. \nhttps:\/\/doi.org\/10.1093\/jac\/39.6.789\n\n.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"813_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/jac\/dkw496","volume":"72","author":"PA De Cock","year":"2017","unstructured":"De Cock PA, Mulla H, Desmet S, De Somer F, McWhinney BC, Ungerer JP, et al. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery. J Antimicrob Chemother. 2017;72(3):791\u2013800. \nhttps:\/\/doi.org\/10.1093\/jac\/dkw496\n\n.","journal-title":"J Antimicrob Chemother"},{"key":"813_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky574","author":"JJ Cies","year":"2019","unstructured":"Cies JJ, Moore WS 2nd, Parker J, Stevens R, Al-Qaqaa Y, Enache A, et al. Pharmacokinetics of cefazolin delivery via the cardiopulmonary bypass circuit priming solution in infants and children. J Antimicrob Chemother. 2019. \nhttps:\/\/doi.org\/10.1093\/jac\/dky574\n\n.","journal-title":"J Antimicrob Chemother."},{"issue":"11","key":"813_CR21","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1128\/AAC.01368-15","volume":"59","author":"PA De Cock","year":"2015","unstructured":"De Cock PA, Standing JF, Barker CI, de Jaeger A, Dhont E, Carlier M, et al. Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children. Antimicrob Agents Chemother. 2015;59(11):7027\u201335. \nhttps:\/\/doi.org\/10.1128\/AAC.01368-15\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"813_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/jac\/25.2.269","volume":"25","author":"AE Jones","year":"1990","unstructured":"Jones AE, Barnes ND, Tasker TC, Horton R. Pharmacokinetics of intravenous amoxycillin and potassium clavulanate in seriously ill children. J Antimicrob Chemother. 1990;25(2):269\u201374. \nhttps:\/\/doi.org\/10.1093\/jac\/25.2.269\n\n.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"813_CR23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1128\/AAC.02089-15","volume":"60","author":"K Nichols","year":"2015","unstructured":"Nichols K, Chung EK, Knoderer CA, Buenger LE, Healy DP, Dees J, et al. Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin and tazobactam in critically ill children. Antimicrob Agents Chemother. 2015;60(1):522\u201331. \nhttps:\/\/doi.org\/10.1128\/AAC.02089-15\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"813_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/INF.0b013e3182a743c7","volume":"33","author":"JJ Cies","year":"2014","unstructured":"Cies JJ, Shankar V, Schlichting C, Kuti JL. Population pharmacokinetics of piperacillin\/tazobactam in critically ill young children. Pediatr Infect Dis J. 2014;33(2):168\u201373. \nhttps:\/\/doi.org\/10.1097\/INF.0b013e3182a743c7\n\n.","journal-title":"Pediatr Infect Dis J."},{"key":"813_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx093","author":"PA De Cock","year":"2017","unstructured":"De Cock PA, van Dijkman SC, de Jaeger A, Willems J, Carlier M, Verstraete AG, et al. Dose optimization of piperacillin\/tazobactam in critically ill children. J Antimicrob Chemother. 2017. \nhttps:\/\/doi.org\/10.1093\/jac\/dkx093\n\n.","journal-title":"J Antimicrob Chemother."},{"key":"813_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0682-1","author":"A B\u00e9ranger","year":"2018","unstructured":"B\u00e9ranger A, Benaboud S, Urien S, Moulin F, Bille E, Lesage F, et al. Piperacillin population pharmacokinetics and dosing regimen optimization in critically ill children with normal and augmented renal clearance. Clin Pharmacokinet. 2018. \nhttps:\/\/doi.org\/10.1007\/s40262-018-0682-1\n\n.","journal-title":"Clin Pharmacokinet"},{"issue":"SUPPL.A","key":"813_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jac\/6.suppl_a.113","volume":"6","author":"HM Von Hattingberg","year":"1980","unstructured":"Von Hattingberg HM, Marget W, Belohradsky BH, Roos R. Pharmacokinetics of cefotaxime in neonates and children: clinical aspects. J Antimicrob Chemother. 1980;6(SUPPL.A):113\u20138. \nhttps:\/\/doi.org\/10.1093\/jac\/6.suppl_a.113\n\n.","journal-title":"J Antimicrob Chemother."},{"issue":"7","key":"813_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40262-017-0602-9","volume":"57","author":"A B\u00e9ranger","year":"2018","unstructured":"B\u00e9ranger A, Oualha M, Urien S, Genuini M, Renolleau S, Aboura R, et al. Population pharmacokinetic model to optimize cefotaxime dosing regimen in critically ill children. Clin Pharmacokinet. 2018;57(7):867\u201375. \nhttps:\/\/doi.org\/10.1007\/s40262-017-0602-9\n\n.","journal-title":"Clin Pharmacokinet"},{"key":"813_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03535-w","author":"SJF Hartman","year":"2019","unstructured":"Hartman SJF, Boeddha NP, Ekinci E, Koch BCP, Donders R, Hazelzet JA, et al. Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis. Eur J Clin Microbiol Infect Dis. 2019. \nhttps:\/\/doi.org\/10.1007\/s10096-019-03535-w\n\n.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"2","key":"813_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1248\/bpb.31.316","volume":"31","author":"HJ Olguin","year":"2008","unstructured":"Olguin HJ, Asseff IL, Vieyra AC, Perez AG, Saldana NG, Quesada AC, et al. Effect of severity disease on the pharmacokinetics of cefuroxime in children with multiple organ system failure. Biol Pharm Bull. 2008;31(2):316\u201320. \nhttps:\/\/doi.org\/10.1248\/bpb.31.316\n\n.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"813_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/jcan.2003.51","volume":"17","author":"D Haessler","year":"2003","unstructured":"Haessler D, Reverdy ME, Neidecker J, Brule P, Ninet J, Lehot JJ. Antibiotic prophylaxis with cefazolin and gentamicin in cardiac surgery for children less than ten kilograms. J Cardiothorac Vasc Anesth. 2003;17(2):221\u20135. \nhttps:\/\/doi.org\/10.1053\/jcan.2003.51\n\n.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"813_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/pcc.0000000000001497","author":"JJ Cies","year":"2018","unstructured":"Cies JJ, Moore WS 2nd, Enache A, Chopra A. Ceftaroline for suspected or confirmed invasive methicillin-resistant staphylococcus aureus: a pharmacokinetic case series. Pediatr Crit Care Med. 2018. \nhttps:\/\/doi.org\/10.1097\/pcc.0000000000001497\n\n.","journal-title":"Pediatr Crit Care Med."},{"key":"813_CR33","unstructured":"Forest Pharmaceutical IT T, Italy. Ceftaroline [package insert]. 2015."},{"issue":"4","key":"813_CR34","doi-asserted-by":"publisher","first-page":"E32","DOI":"10.1002\/phar.1567","volume":"35","author":"JJ Cies","year":"2015","unstructured":"Cies JJ, Moore WS, Calaman S, Brown M, Narayan P, Parker J, et al. Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient. Pharmacotherapy. 2015;35(4):E32\u20136. \nhttps:\/\/doi.org\/10.1002\/phar.1567\n\n.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"813_CR35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5863\/1551-6776-22.4.276","volume":"22","author":"JJ Cies","year":"2017","unstructured":"Cies JJ, Moore WS 2nd, Enache A, Chopra A. Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children. J Pediatr Pharmacol Ther. 2017;22(4):276\u201385. \nhttps:\/\/doi.org\/10.5863\/1551-6776-22.4.276\n\n.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"813_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0091270005283283","volume":"46","author":"X Du","year":"2006","unstructured":"Du X, Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J Clin Pharmacol. 2006;46(1):69\u201375. \nhttps:\/\/doi.org\/10.1177\/0091270005283283\n\n.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"813_CR37","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1128\/aac.39.8.1721","volume":"39","author":"JL Blumer","year":"1995","unstructured":"Blumer JL, Reed MD, Kearns GL, Jacobs RF, Gooch WM 3rd, Yogev R, et al. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children. Antimicrob Agents Chemother. 1995;39(8):1721\u20135. \nhttps:\/\/doi.org\/10.1128\/aac.39.8.1721\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"813_CR38","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1128\/aac.01149-05","volume":"50","author":"E Giannoni","year":"2006","unstructured":"Giannoni E, Moreillon P, Cotting J, Moessinger A, Bille J, Decosterd L, et al. Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob Agents Chemother. 2006;50(7):2563\u20138. \nhttps:\/\/doi.org\/10.1128\/aac.01149-05\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"813_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5863\/1551-6776-22.6.467","volume":"22","author":"JJ Cies","year":"2017","unstructured":"Cies JJ, LaCoursiere RJ, Moore WS 2nd, Chopra A. Therapeutic drug monitoring of prolonged infusion aztreonam for multi-drug resistant Pseudomonas aeruginosa: a case report. J Pediatr Pharmacol Ther. 2017;22(6):467\u201370. \nhttps:\/\/doi.org\/10.5863\/1551-6776-22.6.467\n\n.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"813_CR40","unstructured":"Bristol-Myers-Squibb. Aztreonam (Azactam) [package insert]. Revised Sep 2018."},{"issue":"6","key":"813_CR41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.5863\/1551-6776-21.6.486","volume":"21","author":"S Bonazza","year":"2016","unstructured":"Bonazza S, Bresee LC, Kraft T, Ross BC, Dersch-Mills D. Frequency of and risk factors for acute kidney injury associated with vancomycin use in the pediatric intensive care unit. J Pediatr Pharmacol Ther. 2016;21(6):486\u201393. \nhttps:\/\/doi.org\/10.5863\/1551-6776-21.6.486\n\n.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"813_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw495","author":"PA De Cock","year":"2016","unstructured":"De Cock PA, Desmet S, De Jaeger A, Biarent D, Dhont E, Herck I, et al. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board? J Antimicrob Chemother. 2016. \nhttps:\/\/doi.org\/10.1093\/jac\/dkw495\n\n.","journal-title":"J Antimicrob Chemother."},{"issue":"2","key":"813_CR43","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1097\/MPH.0000000000000470","volume":"38","author":"GT Seixas","year":"2016","unstructured":"Seixas GT, Araujo OR, Silva DC, Arduini RG, Petrilli AS. Vancomycin therapeutic targets and nephrotoxicity in critically ill children with cancer. J Pediatr Hematol Oncol. 2016;38(2):e56\u201362. \nhttps:\/\/doi.org\/10.1097\/MPH.0000000000000470\n\n.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"813_CR44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/phar.1227","volume":"33","author":"JJ Cies","year":"2013","unstructured":"Cies JJ, Shankar V. Nephrotoxicity in patients with vancomycin trough concentrations of 15\u201320 mug\/ml in a pediatric intensive care unit. Pharmacotherapy. 2013;33(4):392\u2013400. \nhttps:\/\/doi.org\/10.1002\/phar.1227\n\n.","journal-title":"Pharmacotherapy."},{"issue":"4","key":"813_CR45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.bjid.2012.06.011","volume":"16","author":"DC Silva","year":"2012","unstructured":"Silva DC, Seixas GT, Araujo OR, Arduini RG, Carlesse FA, Petrilli AS. Vancomycin serum concentrations in pediatric oncologic\/hematologic intensive care patients. Braz J Infect Dis. 2012;16(4):361\u20135. \nhttps:\/\/doi.org\/10.1016\/j.bjid.2012.06.011\n\n.","journal-title":"Braz J Infect Dis."},{"issue":"6","key":"813_CR46","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1097\/PCC.0b013e3181fe4047","volume":"12","author":"GA Giachetto","year":"2011","unstructured":"Giachetto GA, Telechea HM, Speranza N, Oyarzun M, Nanni L, Menchaca A. Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children. Pediatr Crit Care Med. 2011;12(6):e250\u20134. \nhttps:\/\/doi.org\/10.1097\/PCC.0b013e3181fe4047\n\n.","journal-title":"Pediatr Crit Care Med."},{"issue":"1","key":"813_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/jcrc.2000.0150001","volume":"15","author":"ML Glover","year":"2000","unstructured":"Glover ML, Cole E, Wolfsdorf J. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care. 2000;15(1):1\u20134. \nhttps:\/\/doi.org\/10.1053\/jcrc.2000.0150001\n\n.","journal-title":"J Crit Care"},{"issue":"6","key":"813_CR48","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/0310057X9502300603","volume":"23","author":"AG Gous","year":"1995","unstructured":"Gous AG, Dance MD, Lipman J, Luyt DK, Mathivha R, Scribante J. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care. 1995;23(6):678\u201382. \nhttps:\/\/doi.org\/10.1177\/0310057X9502300603\n\n.","journal-title":"Anaesth Intensive Care"},{"issue":"6","key":"813_CR49","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/phar.1259","volume":"33","author":"BR Totapally","year":"2013","unstructured":"Totapally BR, Machado J, Lee H, Paredes A, Raszynski A. Acute kidney injury during vancomycin therapy in critically ill children. Pharmacotherapy. 2013;33(6):598\u2013602. \nhttps:\/\/doi.org\/10.1002\/phar.1259\n\n.","journal-title":"Pharmacotherapy."},{"issue":"2","key":"813_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/afpuc-2015-0025","volume":"62","author":"M Goboova","year":"2015","unstructured":"Goboova M, Kuzelova M, Kissova V, Bodakova D, Martisova E. An adjustment of vancomycin dosing regimen for a young patient with augmented renal clearance: a case report. Acta Fac Pharm Univ Comen. 2015;62(2):1\u20134. \nhttps:\/\/doi.org\/10.1515\/afpuc-2015-0025\n\n.","journal-title":"Acta Fac Pharm Univ Comen."},{"issue":"7","key":"813_CR51","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1097\/PCC.0000000000001198","volume":"18","author":"NR Zane","year":"2017","unstructured":"Zane NR, Reedy MD, Gastonguay MR, Himebauch AS, Ramsey EZ, Topjian AA, et al. A population pharmacokinetic analysis to study the effect of therapeutic hypothermia on vancomycin disposition in children resuscitated from cardiac arrest. Pediatr Crit Care Med. 2017;18(7):e290\u20137. \nhttps:\/\/doi.org\/10.1097\/PCC.0000000000001198\n\n.","journal-title":"Pediatr Crit Care Med."},{"key":"813_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/pcc.0000000000001228","author":"SN Avedissian","year":"2017","unstructured":"Avedissian SN, Bradley E, Zhang D, Bradley JS, Nazer LH, Tran TM, et al. Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients. Pediatr Crit Care Med. 2017. \nhttps:\/\/doi.org\/10.1097\/pcc.0000000000001228\n\n.","journal-title":"Pediatr Crit Care Med."},{"key":"813_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2019","author":"CA Thomas","year":"2017","unstructured":"Thomas CA, Picone A, Menon S, Willis BC. Empiric vancomycin dosing in pediatric patients with congenital heart disease and the impact of cardiopulmonary bypass on trough concentrations. Pharmacotherapy. 2017. \nhttps:\/\/doi.org\/10.1002\/phar.2019\n\n.","journal-title":"Pharmacotherapy."},{"key":"813_CR54","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/pcc.0000000000001335","volume":"1","author":"MR Holsen","year":"2017","unstructured":"Holsen MR, Meaney CJ, Hassinger AB, Fusco NM. Increased risk of acute kidney injury in critically ill children treated with vancomycin and piperacillin\/tazobactam. Pediatr Crit Care Med. 2017;1:4. \nhttps:\/\/doi.org\/10.1097\/pcc.0000000000001335\n\n.","journal-title":"Pediatr Crit Care Med."},{"key":"813_CR55","doi-asserted-by":"publisher","DOI":"10.1097\/pcc.0000000000001474","author":"M Genuini","year":"2018","unstructured":"Genuini M, Oualha M, Bouazza N, Moulin F, Treluyer JM, Lesage F, et al. Achievement of therapeutic vancomycin exposure with continuous infusion in critically ill children. Pediatr Crit Care Med. 2018. \nhttps:\/\/doi.org\/10.1097\/pcc.0000000000001474\n\n.","journal-title":"Pediatr Crit Care Med."},{"key":"813_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00328-8","author":"JC Fitzgerald","year":"2019","unstructured":"Fitzgerald JC, Zane NR, Himebauch AS, Reedy MD, Downes KJ, Topjian AA, et al. Vancomycin prescribing and therapeutic drug monitoring in children with and without acute kidney injury after cardiac arrest. Paediatr Drugs. 2019. \nhttps:\/\/doi.org\/10.1007\/s40272-019-00328-8\n\n.","journal-title":"Paediatr Drugs."},{"issue":"2","key":"813_CR57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5863\/1551-6776-24.2.107","volume":"24","author":"BS Moffett","year":"2019","unstructured":"Moffett BS, Resendiz K, Morris J, Akcan-Arikan A, Checchia PA. Population pharmacokinetics of vancomycin in the pediatric cardiac surgical population. J Pediatr Pharmacol Ther. 2019;24(2):107\u201316. \nhttps:\/\/doi.org\/10.5863\/1551-6776-24.2.107\n\n.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"11","key":"813_CR58","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1023\/B:PHAM.0000048198.56873.d8","volume":"21","author":"JC Lukas","year":"2004","unstructured":"Lukas JC, Karikas G, Gazouli M, Kalabalikis P, Hatzis T, Macheras P. Pharmacokinetics of teicoplanin in an ICU population of children and infants. Pharm Res. 2004;21(11):2064\u201371. \nhttps:\/\/doi.org\/10.1023\/B:PHAM.0000048198.56873.d8\n\n.","journal-title":"Pharm Res"},{"issue":"3","key":"813_CR59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/jac\/44.3.407","volume":"44","author":"A Sanchez","year":"1999","unstructured":"Sanchez A, Lopez-Herce J, Cueto E, Carrillo A, Moral R. Teicoplanin pharmacokinetics in critically ill paediatric patients. J Antimicrob Chemother. 1999;44(3):407\u20139. \nhttps:\/\/doi.org\/10.1093\/jac\/44.3.407\n\n.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"813_CR60","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/FTD.0000000000000016","volume":"36","author":"M Zakova","year":"2014","unstructured":"Zakova M, Pong S, Trope A, Atenafu EG, Papaioannou V, Bitnun SA, et al. Dose derivation of once-daily dosing guidelines for gentamicin in critically ill pediatric patients. Ther Drug Monit. 2014;36(3):288\u201394. \nhttps:\/\/doi.org\/10.1097\/FTD.0000000000000016\n\n.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"813_CR61","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/PCC.0b013e3181b80693","volume":"11","author":"SA Lopez","year":"2010","unstructured":"Lopez SA, Mulla H, Durward A, Tibby SM. Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness. Pediatr Crit Care Med. 2010;11(2):267\u201374. \nhttps:\/\/doi.org\/10.1097\/PCC.0b013e3181b80693\n\n.","journal-title":"Pediatr Crit Care Med."},{"issue":"9","key":"813_CR62","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/00006454-199309000-00002","volume":"12","author":"DM Kraus","year":"1993","unstructured":"Kraus DM, Dusik CM, Rodvold KA, Campbell MM, Kecskes SA. Bayesian forecasting of gentamicin pharmacokinetics in pediatric intensive-care unit patients. Pediatr Infect Dis J. 1993;12(9):713\u20138. \nhttps:\/\/doi.org\/10.1097\/00006454-199309000-00002\n\n.","journal-title":"Pediatr Infect Dis J."},{"key":"813_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jac\/27.suppl_c.81","volume":"27 Suppl C","author":"PE Marik","year":"1991","unstructured":"Marik PE, Havlik I, Monteagudo FS, Lipman J. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. J Antimicrob Chemother. 1991;27 Suppl C:81\u20139. \nhttps:\/\/doi.org\/10.1093\/jac\/27.suppl_c.81\n\n.","journal-title":"J Antimicrob Chemother."},{"issue":"7","key":"813_CR64","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1128\/AAC.40.7.1682","volume":"40","author":"F Bressolle","year":"1996","unstructured":"Bressolle F, Gouby A, Martinez JM, Joubert P, Saissi G, Guillaud R, et al. Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother. 1996;40(7):1682\u20139. \nhttps:\/\/doi.org\/10.1128\/AAC.40.7.1682\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"813_CR65","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.burns.2013.06.015","volume":"40","author":"CM Sherwin","year":"2014","unstructured":"Sherwin CM, Wead S, Stockmann C, Healy D, Spigarelli MG, Neely A, et al. Amikacin population pharmacokinetics among paediatric burn patients. Burns. 2014;40(2):311\u20138. \nhttps:\/\/doi.org\/10.1016\/j.burns.2013.06.015\n\n.","journal-title":"Burns."},{"issue":"5","key":"813_CR66","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/BF01720910","volume":"20","author":"BP Wagner","year":"1994","unstructured":"Wagner BP, Pfenninger J. Once daily dosing of netilmicin in neonatal and pediatric intensive care. Intensive Care Med. 1994;20(5):365\u20137. \nhttps:\/\/doi.org\/10.1007\/BF01720910\n\n.","journal-title":"Intensive Care Med"},{"issue":"5","key":"813_CR67","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1592\/phco.26.5.694","volume":"26","author":"RL Akins","year":"2006","unstructured":"Akins RL, Haase MR, Levy EN. Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis. Pharmacotherapy. 2006;26(5):694\u20138. \nhttps:\/\/doi.org\/10.1592\/phco.26.5.694\n\n.","journal-title":"Pharmacotherapy."},{"issue":"4","key":"813_CR68","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5863\/1551-6776-22.4.300","volume":"22","author":"S Morris","year":"2017","unstructured":"Morris S, Gould K, Ferguson LP. The use of daptomycin to treat methicillin-resistant Staphylococcus epidermidis bacteremia in a critically ill child with renal failure. J Pediatr Pharmacol Ther. 2017;22(4):300\u20133. \nhttps:\/\/doi.org\/10.5863\/1551-6776-22.4.300\n\n.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"813_CR69","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/aac.02462-17","volume":"62","author":"C Antachopoulos","year":"2018","unstructured":"Antachopoulos C, Ilia S, Kadiltzoglou P, Baira E, Dokoumetzidis A, Gikas E, et al. Pharmacokinetics of daptomycin in critically ill pediatric patients. Antimicrob Agents Chemother. 2018;62:6. \nhttps:\/\/doi.org\/10.1128\/aac.02462-17\n\n.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"813_CR70","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00134-002-1212-y","volume":"28","author":"J Lipman","year":"2002","unstructured":"Lipman J, Gous AG, Mathivha LR, Tshukutsoane S, Scribante J, Hon H, et al. Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? Intensive Care Med. 2002;28(4):493\u2013500. \nhttps:\/\/doi.org\/10.1007\/s00134-002-1212-y\n\n.","journal-title":"Intensive Care Med"},{"issue":"1","key":"813_CR71","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jac\/dkh299","volume":"54","author":"P Malacarne","year":"2004","unstructured":"Malacarne P, Rossi C, Bertolini G, GiVi TIG. Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre study. J Antimicrob Chemother. 2004;54(1):221\u20134. \nhttps:\/\/doi.org\/10.1093\/jac\/dkh299\n\n.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"813_CR72","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4103\/0972-5229.182197","volume":"20","author":"Q Abbas","year":"2016","unstructured":"Abbas Q, Ul Haq A, Kumar R, Ali SA, Hussain K, Shakoor S. Evaluation of antibiotic use in Pediatric Intensive Care Unit of a developing country. Indian J Crit Care Med. 2016;20(5):291\u20134. \nhttps:\/\/doi.org\/10.4103\/0972-5229.182197\n\n.","journal-title":"Indian J Crit Care Med."},{"issue":"5","key":"813_CR73","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ijantimicag.2012.06.022","volume":"40","author":"M Carlier","year":"2012","unstructured":"Carlier M, Stove V, Roberts JA, Van de Velde E, De Waele JJ, Verstraete AG. Quantification of seven beta-lactam antibiotics and two beta-lactamase inhibitors in human plasma using a validated UPLC-MS\/MS method. Int J Antimicrob Agents. 2012;40(5):416\u201322. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2012.06.022\n\n.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"813_CR74","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijantimicag.2009.10.008","volume":"35","author":"JA Roberts","year":"2010","unstructured":"Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2010;35(2):156\u201363. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2009.10.008\n\n.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"813_CR75","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1128\/aac.20.4.487","volume":"20","author":"DA Kafetzis","year":"1981","unstructured":"Kafetzis DA, Brater DC, Kanarios J, Sinaniotis CA, Papadatos CJ. Clinical pharmacology of cefotaxime in pediatric patients. Antimicrob Agents Chemother. 1981;20(4):487\u201390. \nhttps:\/\/doi.org\/10.1128\/aac.20.4.487\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"813_CR76","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3109\/08880019809014017","volume":"15","author":"N Krivoy","year":"1998","unstructured":"Krivoy N, Peleg S, Postovsky S, Ben Arush MW. Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients. Pediatr Hematol Oncol. 1998;15(4):333\u20138. \nhttps:\/\/doi.org\/10.3109\/08880019809014017\n\n.","journal-title":"Pediatr Hematol Oncol"},{"issue":"8","key":"813_CR77","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/00006454-199508000-00004","volume":"14","author":"D Chang","year":"1995","unstructured":"Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J. 1995;14(8):667\u201373.","journal-title":"Pediatr Infect Dis J."},{"issue":"2","key":"813_CR78","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijantimicag.2014.03.009","volume":"44","author":"L Escobar","year":"2014","unstructured":"Escobar L, Andresen M, Downey P, Gai MN, Regueira T, Borquez T, et al. Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. Int J Antimicrob Agents. 2014;44(2):163\u20137. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2014.03.009\n\n.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"813_CR79","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2710.2006.00762.x","volume":"31","author":"P Llopis-Salvia","year":"2006","unstructured":"Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther. 2006;31(5):447\u201354. \nhttps:\/\/doi.org\/10.1111\/j.1365-2710.2006.00762.x\n\n.","journal-title":"J Clin Pharm Ther"},{"issue":"277","key":"813_CR80","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/oxfordjournals.qjmed.a068460","volume":"75","author":"S Teelucksingh","year":"1990","unstructured":"Teelucksingh S, Padfield PL, Edwards CR. Systemic capillary leak syndrome. Q J Med. 1990;75(277):515\u201324. \nhttps:\/\/doi.org\/10.1093\/oxfordjournals.qjmed.a068460\n\n.","journal-title":"Q J Med."},{"issue":"12","key":"813_CR81","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1128\/AAC.00951-13","volume":"57","author":"G Wong","year":"2013","unstructured":"Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, et al. Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. 2013;57(12):6165\u201370. \nhttps:\/\/doi.org\/10.1128\/AAC.00951-13\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"813_CR82","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ijantimicag.2014.01.023","volume":"43","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Stove V, De Waele JJ, Sipinkoski B, McWhinney B, Ungerer JP, et al. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI study. Int J Antimicrob Agents. 2014;43(5):423\u201330. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2014.01.023\n\n.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"813_CR83","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1128\/aac.38.5.931","volume":"38","author":"JW Mouton","year":"1994","unstructured":"Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38(5):931\u20136. \nhttps:\/\/doi.org\/10.1128\/aac.38.5.931\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"813_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","volume":"26","author":"WA Craig","year":"1998","unstructured":"Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1\u201310. \nhttps:\/\/doi.org\/10.1086\/516284\n\nquiz 1-2.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"813_CR85","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1164\/rccm.201510-2114OC","volume":"194","author":"NJ Vet","year":"2016","unstructured":"Vet NJ, Brussee JM, de Hoog M, Mooij MG, Verlaat CW, Jerchel IS, et al. Inflammation and organ failure severely affect midazolam clearance in critically ill children. Am J Respir Crit Care Med. 2016;194(1):58\u201366. \nhttps:\/\/doi.org\/10.1164\/rccm.201510-2114OC\n\n.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"813_CR86","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/cpt.757","volume":"102","author":"JO Miners","year":"2017","unstructured":"Miners JO, Yang X, Knights KM, Zhang L. The role of the kidney in drug elimination: transport, metabolism, and the impact of kidney disease on drug clearance. Clin Pharmacol Ther. 2017;102(3):436\u201349. \nhttps:\/\/doi.org\/10.1002\/cpt.757\n\n.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"813_CR87","doi-asserted-by":"publisher","first-page":"518","DOI":"10.4103\/0972-5229.138156","volume":"18","author":"M Ashraf","year":"2014","unstructured":"Ashraf M, Shahzad N, Irshad M, Hussain SQ, Ahmed P. Pediatric acute kidney injury: a syndrome under paradigm shift. Indian J Crit Care Med. 2014;18(8):518\u201326. \nhttps:\/\/doi.org\/10.4103\/0972-5229.138156\n\n.","journal-title":"Indian J Crit Care Med."},{"key":"813_CR88","doi-asserted-by":"publisher","first-page":"k4891","DOI":"10.1136\/bmj.k4891","volume":"364","author":"JT Poston","year":"2019","unstructured":"Poston JT, Koyner JL. Sepsis associated acute kidney injury. BMJ. 2019;364:k4891. \nhttps:\/\/doi.org\/10.1136\/bmj.k4891\n\n.","journal-title":"BMJ"},{"issue":"4","key":"813_CR89","doi-asserted-by":"publisher","first-page":"R84","DOI":"10.1186\/cc6089","volume":"11","author":"M Zappitelli","year":"2007","unstructured":"Zappitelli M, Washburn KK, Arikan AA, Loftis L, Ma Q, Devarajan P, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care. 2007;11(4):R84. \nhttps:\/\/doi.org\/10.1186\/cc6089\n\n.","journal-title":"Crit Care"},{"issue":"2","key":"813_CR90","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00467-005-2105-4","volume":"21","author":"N Chen","year":"2006","unstructured":"Chen N, Aleksa K, Woodland C, Rieder M, Koren G. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol. 2006;21(2):160\u20138. \nhttps:\/\/doi.org\/10.1007\/s00467-005-2105-4\n\n.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"813_CR91","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1208\/ps020103","volume":"2","author":"WL Hayton","year":"2000","unstructured":"Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS Pharm Sci. 2000;2(1):E3. \nhttps:\/\/doi.org\/10.1208\/ps020103\n\n.","journal-title":"AAPS Pharm Sci."},{"issue":"3","key":"813_CR92","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","volume":"73","author":"JW Mouton","year":"2018","unstructured":"Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC-based dose adjustment: facts and fables. J Antimicrob Chemother. 2018;73(3):564\u20138. \nhttps:\/\/doi.org\/10.1093\/jac\/dkx427\n\n.","journal-title":"J Antimicrob Chemother"},{"key":"813_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejps.2018.09.008","volume":"125","author":"JW Mouton","year":"2018","unstructured":"Mouton JW. Soup with or without meatballs: impact of nutritional factors on the MIC, kill-rates and growth-rates. Eur J Pharm Sci. 2018;125:23\u20137. \nhttps:\/\/doi.org\/10.1016\/j.ejps.2018.09.008\n\n.","journal-title":"Eur J Pharm Sci"},{"key":"813_CR94","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2832-4","author":"H Woksepp","year":"2016","unstructured":"Woksepp H, Hallgren A, Borgstrom S, Kullberg F, Wimmerstedt A, Oscarsson A, et al. High target attainment for beta-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied. Eur J Clin Microbiol Infect Dis. 2016. \nhttps:\/\/doi.org\/10.1007\/s10096-016-2832-4\n\n.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"5","key":"813_CR95","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/jac\/dkv487","volume":"71","author":"M Kumaraswamy","year":"2016","unstructured":"Kumaraswamy M, Lin L, Olson J, Sun CF, Nonejuie P, Corriden R, et al. Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia. J Antimicrob Chemother. 2016;71(5):1264\u20139. \nhttps:\/\/doi.org\/10.1093\/jac\/dkv487\n\n.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"813_CR96","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1128\/AAC.00182-11","volume":"55","author":"EI Nielsen","year":"2011","unstructured":"Nielsen EI, Cars O, Friberg LE. Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother. 2011;55(10):4619\u201330. \nhttps:\/\/doi.org\/10.1128\/AAC.00182-11\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"813_CR97","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Societe Francaise de Pharmacologie et Therapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Societe Francaise d\u2019Anesthesie et Reanimation-SFAR). Crit Care. 2019;23(1):104. \nhttps:\/\/doi.org\/10.1186\/s13054-019-2378-9\n\n.","journal-title":"Crit Care"},{"issue":"10","key":"813_CR98","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","volume":"42","author":"MH Abdul-Aziz","year":"2016","unstructured":"Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535\u201345. \nhttps:\/\/doi.org\/10.1007\/s00134-015-4188-0\n\n.","journal-title":"Intensive Care Med"},{"issue":"2","key":"813_CR99","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cid\/cis857","volume":"56","author":"ME Falagas","year":"2013","unstructured":"Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin\/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(2):272\u201382. \nhttps:\/\/doi.org\/10.1093\/cid\/cis857\n\n.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"813_CR100","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","volume":"47","author":"JJ Hao","year":"2016","unstructured":"Hao JJ, Chen H, Zhou JX. Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47(1):28\u201335. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2015.10.019\n\n.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"813_CR101","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024oc","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent beta-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681\u201391. \nhttps:\/\/doi.org\/10.1164\/rccm.201601-0024oc\n\n.","journal-title":"Am J Respir Crit Care Med."},{"issue":"6","key":"813_CR102","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1097\/CCM.0b013e3181a0054d","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med. 2009;37(6):2071\u20138. \nhttps:\/\/doi.org\/10.1097\/CCM.0b013e3181a0054d\n\n.","journal-title":"Crit Care Med"},{"issue":"5","key":"813_CR103","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijantimicag.2014.01.027","volume":"43","author":"J Teo","year":"2014","unstructured":"Teo J, Liew Y, Lee W, Kwa AL. Prolonged infusion versus intermittent boluses of beta-lactam antibiotics for treatment of acute infections: a meta-analysis. Int J Antimicrob Agents. 2014;43(5):403\u201311. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2014.01.027\n\n.","journal-title":"Int J Antimicrob Agents"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00813-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T23:41:17Z","timestamp":1597794077000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00813-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,20]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00813-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,20]]},"assertion":[{"value":"20 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Financial support from institutions Radboudumc, Nijmegen, The Netherlands.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Stan J. F. Hartman, Roger J. Br\u00fcggemann, Lynn Orri\u00ebns, Nada Dia, Michiel F. Schreuder and Saskia N. de Wildt declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}